Summary
GlobalData's “Partnerships, Licensing, Investments and M&A Deals and Trends for September 2015 in Pharmaceuticals” report is an essential source of data and trend analysis on partnerships, licensing, mergers and acquisitions (M&As) and financings in the pharmaceuticals industry. The report provides detailed information on partnership and licensing transactions, M&As, equity/debt offerings, private equity, and venture financing registered in the pharmaceuticals industry in September 2015. The report portrays detailed comparative data on the number of deals and their value in the last six months, subdivided by deal types, various therapy areas, and geographies. Additionally, the report provides information on the top financial advisory firms in the pharmaceuticals industry.
Data presented in this report is derived from GlobalData’s proprietary in-house Pharmaceuticals eTrack deals database and primary and secondary research.
Complete report details @ https://www.wiseguyreports.com/reports/partnerships-licensing-investments-and-m-a-deals-and-trends-for-september-2015-in-pharmaceuticals .
Scope
- Analysis of the market trends for the pharmaceutical industry in the global arena.
- Review of deal trends in the cardiovascular, central nervous system, dermatology, ear nose throat disorders, gastrointestinal, genito urinary system and sex hormones, hematological disorders, hormonal disorders, immunology, infectious disease, male health, metabolic disorders, mouth and dental disorders, musculoskeletal, oncology, ophthalmology, respiratory, toxicology, and women's health segments.
- Analysis of partnerships, licensing, M&As, equity/debt offerings, private equity, and venture financing deals in the pharmaceutical industry.
- Analysis of therapy areas which are very active in terms of venture capital financing, partnerships, licensing agreements, equity/debt offerings, and M&As.
- Analysis of deals based on different payment modes, including upfront and milestone payments, primarily in partnerships and licensing agreements in the pharmaceutical industry.
- Analysis of partnership and licensing deals based on clinical stage of development of products.
- Summary of the pharmaceutical deals globally in the six months.
- Information on the top deals happened in the pharmaceutical industry.
- Geographies covered include - North America, Europe, Asia Pacific, South & Central America, and the Middle East & Africa.
- League tables of financial advisors in M&As and equity/debt offerings. This includes key advisors such as Morgan Stanley, Credit Suisse, and Goldman Sachs.
Make an enquiry before buying report @ https://www.wiseguyreports.com/enquiry/partnerships-licensing-investments-and-m-a-deals-and-trends-for-september-2015-in-pharmaceuticals .
Table of Contents
Partner Relations & Marketing Manager
sales@wiseguyreports.com
Ph: +1-646-845-9349 (US)
GlobalData's “Partnerships, Licensing, Investments and M&A Deals and Trends for September 2015 in Pharmaceuticals” report is an essential source of data and trend analysis on partnerships, licensing, mergers and acquisitions (M&As) and financings in the pharmaceuticals industry. The report provides detailed information on partnership and licensing transactions, M&As, equity/debt offerings, private equity, and venture financing registered in the pharmaceuticals industry in September 2015. The report portrays detailed comparative data on the number of deals and their value in the last six months, subdivided by deal types, various therapy areas, and geographies. Additionally, the report provides information on the top financial advisory firms in the pharmaceuticals industry.
Data presented in this report is derived from GlobalData’s proprietary in-house Pharmaceuticals eTrack deals database and primary and secondary research.
Complete report details @ https://www.wiseguyreports.com/reports/partnerships-licensing-investments-and-m-a-deals-and-trends-for-september-2015-in-pharmaceuticals .
Scope
- Analysis of the market trends for the pharmaceutical industry in the global arena.
- Review of deal trends in the cardiovascular, central nervous system, dermatology, ear nose throat disorders, gastrointestinal, genito urinary system and sex hormones, hematological disorders, hormonal disorders, immunology, infectious disease, male health, metabolic disorders, mouth and dental disorders, musculoskeletal, oncology, ophthalmology, respiratory, toxicology, and women's health segments.
- Analysis of partnerships, licensing, M&As, equity/debt offerings, private equity, and venture financing deals in the pharmaceutical industry.
- Analysis of therapy areas which are very active in terms of venture capital financing, partnerships, licensing agreements, equity/debt offerings, and M&As.
- Analysis of deals based on different payment modes, including upfront and milestone payments, primarily in partnerships and licensing agreements in the pharmaceutical industry.
- Analysis of partnership and licensing deals based on clinical stage of development of products.
- Summary of the pharmaceutical deals globally in the six months.
- Information on the top deals happened in the pharmaceutical industry.
- Geographies covered include - North America, Europe, Asia Pacific, South & Central America, and the Middle East & Africa.
- League tables of financial advisors in M&As and equity/debt offerings. This includes key advisors such as Morgan Stanley, Credit Suisse, and Goldman Sachs.
Make an enquiry before buying report @ https://www.wiseguyreports.com/enquiry/partnerships-licensing-investments-and-m-a-deals-and-trends-for-september-2015-in-pharmaceuticals .
Table of Contents
1
Table of Contents 2
1.1 List of Tables 6
1.2 List of Figures 9
2 Pharmaceuticals & Healthcare, Global, Deal Summary 12
2.1 Pharmaceuticals & Healthcare, Global, Deal Analysis, September 2015 12
2.2 Pharmaceuticals & Healthcare, Global, Major Deals, September 2015 14
2.2.1 Gilead Sciences Raises USD10 Billion in Public Offering Notes 14
2.2.2 Biogen Raises USD6 Billion in Public Offering Notes 14
2.2.3 Concordia Healthcare Acquires Amdipharm Mercury for USD3.54 Billion 15
2.2.4 Sanofi Prices Public Offering of Notes for USD2.3 Billion 16
2.2.5 Amgen Enters into Licensing Agreement with Xencor 16
2.3 Pharmaceuticals & Healthcare, Global, by Type, Number of Deals, September 2015 18
2.4 Pharmaceuticals & Healthcare, Global, by Type, Deal Values, September 2015 19
3 Pharmaceuticals and Healthcare, Global, Deals, Summary, by Type 20
3.1 Pharmaceuticals & Healthcare, Global, M&A, September 2015 20
3.1.1 Top M&A Deals in September 2015 21
3.1.2 Pharmaceuticals & Healthcare, Global, M&A Deals by Therapy Area, April 2015 - September 2015 22
3.2 Pharmaceuticals & Healthcare, Global, Equity Offering Deals, September 2015 24
3.2.1 Top Equity Offering Deals in September 2015 25
1.1 List of Tables 6
1.2 List of Figures 9
2 Pharmaceuticals & Healthcare, Global, Deal Summary 12
2.1 Pharmaceuticals & Healthcare, Global, Deal Analysis, September 2015 12
2.2 Pharmaceuticals & Healthcare, Global, Major Deals, September 2015 14
2.2.1 Gilead Sciences Raises USD10 Billion in Public Offering Notes 14
2.2.2 Biogen Raises USD6 Billion in Public Offering Notes 14
2.2.3 Concordia Healthcare Acquires Amdipharm Mercury for USD3.54 Billion 15
2.2.4 Sanofi Prices Public Offering of Notes for USD2.3 Billion 16
2.2.5 Amgen Enters into Licensing Agreement with Xencor 16
2.3 Pharmaceuticals & Healthcare, Global, by Type, Number of Deals, September 2015 18
2.4 Pharmaceuticals & Healthcare, Global, by Type, Deal Values, September 2015 19
3 Pharmaceuticals and Healthcare, Global, Deals, Summary, by Type 20
3.1 Pharmaceuticals & Healthcare, Global, M&A, September 2015 20
3.1.1 Top M&A Deals in September 2015 21
3.1.2 Pharmaceuticals & Healthcare, Global, M&A Deals by Therapy Area, April 2015 - September 2015 22
3.2 Pharmaceuticals & Healthcare, Global, Equity Offering Deals, September 2015 24
3.2.1 Top Equity Offering Deals in September 2015 25
......
Check Discount on this report @ https://www.wiseguyreports.com/check_discount/partnerships-licensing-investments-and-m-a-deals-and-trends-for-september-2015-in-pharmaceuticals
.
Contact US:
NORAH TRENTPartner Relations & Marketing Manager
sales@wiseguyreports.com
Ph: +1-646-845-9349 (US)
Ph: +44 208 133 9349 (UK)
No comments:
Post a Comment